MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

GILD · NASDAQ-GS

Gilead Sciences, Inc.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances)

Reference price$134.32As of Jul 28, 2026
Market capitalization$167B
52-week range$108.46–$157.29
S&P 500 portfolio weight0.25%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$120.00-10.7% vs. reference
Average$159.05+18.4% vs. reference
High$180.00+34.0% vs. reference
17 Buy3 Hold0 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportAug 4, 2026Jun 2026
Consensus EPS-$7.095 estimates
Expected range-$7.34–-$6.99Low to high EPS
Dec 2026-$0.77Street EPS consensus
Dec 2027$9.73Street EPS consensus
Dec 2028$9.87Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue+2.4% YoY$29.44B$28.75B
Operating income$10.02B$1.66B
Net income$8.51B$0.48B
Operating cash flow$10.02B$10.83B
Capital expenditures($0.56B)($0.52B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

BNK Invest

Notable ETF Inflow Detected - XLV, MRK, AMGN, GILD

Zacks

Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for

Zacks

Can Gilead's Efforts to Develop New Treatments Solidify HIV Franchise?

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.